Vascular Endothelial Growth Factor-121, Recombinant, Human (VEGF-121)

Vascular endothelial growth factor-A was originally isolated from tumor cells and referred to as Tumor Angiogenesis Factor or Vascular Permeability Factor. Although expressed at high levels in certain tumor-derived cells it is produced by a wide variety of cell types. In addition to stimulating vascular growth and vascular permeability it may play a role in stimulating Vasolidation via nitric oxide-dependent pathways. Alternative splicing of the mRNA for VEGF-A results in several isoforms of the protein being produced. Rat and bovine VEGF are one amino acid shorter than the human factor, and the bovine and human sequences show a homology of 95 percent. In contrast to other factors mitogenic for endothelial cells such as FGF-1, FGF-2 and PDGF, VEGF is synthesized as a precursor containing a typical hydrophobic secretory signal sequence of 26 amino acids. Glycosylation is not required for efficient secretion of VEGF.\n\nRecombinant Human VEGF-121 is a double, non-glycosylated, polypeptide chain containing 121 amino acids and having a molecular mass of 28423 Dalton. VEGF-121 circulates more freely than other VEGF forms, which bind more tightly with vascular heparin sulfates.\n\nSequence:\nThe sequence of the first five N-terminal amino acids was determined and was found to be Ala-Pro-Met-Ala-Glu.\n\nDimers and Aggregates:\n(same/less than) 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nBiological Activity:\nThe biological activity is determined by the dose-dependent stimulation of the proliferation of human umbilical vein endothelial cells (HUVEC) using a concentration range of 0.2-0.4ng/ml.\n\nProtein Content:\nProtein quantitation was carried out by two independent methods:\n1. UV spectroscopy at 280 nm using the absorbency value of 0.2875 as the extinction coefficient for a 0.1% (1mg/ml) solution. This value is calculated by the PC GENE computer analysis program of protein sequences (IntelliGenetics). \n2. Analysis by RP-HPLC, using a calibrated solution of VEGF as a Reference Standard.\n\nStorage and Stability:\nLyophilized powder may be stored at 4 degrees C for short-term only. Reconstitute to nominal volume by adding sterile dH2O, 0.1% HSA or BSA and store at -20 degrees C. Reconstituted product is stable for 12 months at -20 degrees C. For maximum recovery of product, centrifuge the original vial prior to removing the cap. Further dilutions can be made in assay buffer.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

V2110-04R

Size

2ug

Form

Supplied as a lyophilized powder. No additives. Reconstitute in ddH2O, 0.1% HSA or BSA to >100ug/ml, which can then be further diluted to other aqueous solutions.

Purity

(same/more than) 98% by RP-HPLC, FPLC, or reducing/non-reducing SDS-PAGE Silver Stain. Chromatographically purified. .(same/less than)0.1ng/ug (IEU/ug).

References

1. Overproduction of VEGF concomitantly expressed with its receptors promotes growth and survival of melanoma cells through MAPK and PI3K signaling. Graells J, Vinyals A, Llorens A, Fabra A, J Invest Dermatol 2004 Dec;123(6):1151-61 2. Vascular endothelial growth factor A (VEGF-A) is involved in guidance of VEGF receptor-positive cells to the anterior portion of early embryos. Hiratsuka S, Kataoka Y, Nakamura K, Maru Y, Mol Cell Biol 2005 Jan;25(1):355-63 3. GM-CSF induces expression of soluble VEGF receptor-1 from human monocytes and inhibits angiogenesis in mice. Eubank TD, Roberts R, Wang Y, Immunity 2004 Dec;21(6):831-42 4. ErbB2 overexpression in mammary cells upregulates VEGF through the core promoter. Loureiro RM, Maharaj AS, Muller WJ, Biochem Biophys Res Commun 2005 Jan 14;326(2):455-65 5. Localization of the VEGF and angiopoietin genes in uterine carcinosarcoma. Emoto M, Charnock-Jones DS, Ishiguro M, Hachisuga T, Gynecol Oncol 2004 Dec;95(3):474-82 6. Differential effects of antiangiogenic compounds in neovascularization, leukocyte recruitment, VEGF production, and tumor growth in mice. Belo AV, Barcelos LS, Ferreira MA, Cancer Invest 2004;22(5):723-9.